The Journal of Thoracic and Cardiovascular Surgery
Volume 138, Issue 4 , Pages 831-836, October 2009

Impact of tumor length on long-term survival of pT1 esophageal adenocarcinoma

  • William D. Bolton, MD

      Affiliations

    • Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Tex
  • ,
  • Wayne L. Hofstetter, MD

      Affiliations

    • Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Tex
  • ,
  • Ashleigh M. Francis, BS

      Affiliations

    • Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Tex
  • ,
  • Arlene M. Correa, MD

      Affiliations

    • Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Tex
  • ,
  • Jaffer A. Ajani, MD

      Affiliations

    • Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Tex
  • ,
  • Manoop S. Bhutani, MD

      Affiliations

    • Department of Diagnostic Radiology, The University of Texas M. D. Anderson Cancer Center, Houston, Tex
  • ,
  • Jeremy Erasmus, MD

      Affiliations

    • Department of Gastrointestinal Medicine and Nutrition, The University of Texas M. D. Anderson Cancer Center, Houston, Tex
  • ,
  • Ritsuko Komaki, MD

      Affiliations

    • Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Tex
  • ,
  • Dipen M. Maru, MD

      Affiliations

    • Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Tex
  • ,
  • Reza J. Mehran, MD

      Affiliations

    • Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Tex
  • ,
  • David C. Rice, MD

      Affiliations

    • Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Tex
  • ,
  • Jack A. Roth, MD

      Affiliations

    • Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Tex
  • ,
  • Ara A. Vaporciyan, MD

      Affiliations

    • Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Tex
  • ,
  • Garrett L. Walsh, MD

      Affiliations

    • Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Tex
  • ,
  • Stephen G. Swisher, MD

      Affiliations

    • Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Tex
    • Corresponding Author InformationAddress for reprints: Stephen G. Swisher, MD, The University of Texas M. D. Anderson Cancer Center, Department of Thoracic and Cardiovascular Surgery, 1515 Holcombe Blvd, Box 445, Houston, TX 77030.

Received 9 May 2008; received in revised form 16 January 2009; accepted 2 February 2009. published online 10 April 2009.

Introduction

The impact of esophageal tumor length on pT1 esophageal adenocarcinoma has not been well evaluated.

Methods

Case histories of all patients (n = 133) undergoing esophageal resection from 1979 to 2007 with pT1 adenocarcinoma of the esophagus were reviewed. Univariate and multivariate analyses of esophageal tumor length and other standard prognostic factors were performed.

Results

Patients with early-stage pT1 esophageal adenocarcinoma with tumors less than 3 cm demonstrate decreased long-term survival (3 years: >3 cm = 46% vs 93%; P < .001) and higher risk of lymph node involvement (lymph node positive: >3 cm = 47% vs 10%; P < .001). Multivariable analysis shows that esophageal tumor length (>3 cm) is an independent risk factor for survival in patients with pT1 early-stage esophageal cancer (hazard ratio: 4.8, 95% confidence intervals: 1.4–16.5; P < .001) even when controlled for submucosal involvement, lymph node involvement, and lymphatic/vascular invasion status. In combination with submucosal involvement, esophageal tumor length (>3 cm) identifies a high-risk population of pT1 esophageal adenocarcinoma (3 years: group 1 [0 risk factors] = 100%, group 2 [1 risk factor] = 87%, and group 3 [2 risk factors] = 33%; P < .001).

Conclusions

This study demonstrates that esophageal tumor length (>3 cm) is a risk factor for long-term survival and lymph node involvement in early-stage pT1 esophageal adenocarcinoma. Esophageal tumor length (>3 cm) in combination with submucosal involvement may help to identify a high-risk group of patients with pT1 esophageal adenocarcinoma.

Abbreviations and Acronyms: CI, confidence intervals, CT, computed tomography, HR, hazard ratio, LVI, lymphatic/vascular invasion, MDACC, M. D. Anderson Cancer Center, PET, positron emission tomography

CTSNet classification: 7

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This work was supported by the Homer Flower Gene Therapy Research Fund, the Charles Rogers Gene Therapy Fund, the Flora & Stuart Mason Lung Cancer Research Fund, the Charles B. Swank Memorial Fund for Esophageal Cancer Research, the George O. Sweeney Fund for Esophageal Cancer Research, the Phalan Thoracic Gene Therapy Fund, and the M. W. Elkins Endowed Fund for Thoracic Surgical Oncology.

PII: S0022-5223(09)00176-7

doi:10.1016/j.jtcvs.2009.02.003

The Journal of Thoracic and Cardiovascular Surgery
Volume 138, Issue 4 , Pages 831-836, October 2009